Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs

ACS Chemical Biology

Volumn 4, Issue 1, 2009, Pages 65-74

  Cherkasov, Artem ^a   Hilpert, Kai ^a   Jenssen, Håvard ^a   Fjell, Christopher D ^a   Waldbrook, Matt ^a   Mullaly, Sarah C ^a   Volkmer, Rudolf ^b   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE HHC 10; PEPTIDE HHC 36; PEPTIDE LIBRARY; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; PEPTIDE;

AMINO ACID COMPOSITION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL INTELLIGENCE; ARTIFICIAL NEURAL NETWORK; COMPUTER AIDED DESIGN; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; DRUG DESIGN; FEMALE; INFECTION PREVENTION; MACHINE LEARNING; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; PATHOGENICITY; PSEUDOMONAS AERUGINOSA;

ANIMALIA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ARTIFICIAL INTELLIGENCE; COMPUTER SIMULATION; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; HUMANS; MICE; PEPTIDE LIBRARY; PEPTIDES; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 60749130267     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb800240j     Document Type: Article

References (39)

1. Hancock, R. E. (2007) The end of an era? Nat Rev. Drug Discovery 6, 28.
2. Theuretzbacher, U., and Toney, J. H. (2006) Nature's clarion call of antibacterial resistance: are we listening? Curr. Opin. Invest. Drugs 7, 158-166.
3. Projan, S. J. (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430.
4. Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., and Edwards, J. E., Jr. (2004) Trends in antimicrobial drug development: implications for the future, Clin. Infect Dis. 38, 1279-1286.
5. Hancock, R. E., and Sahl, H. G. (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies, Nat. Biotechnol. 24, 1551-1557.
6. Oppenheim, J. J., and Yang, D. (2005) Alarmins: chemotactic activators of immune responses, Curr. Opin. Immunol. 17, 359-365.
7. Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms, Nature 415, 389-395.
8. Jenssen, H., Hamill, P., and Hancock, R. E. (2006) Peptide antimicrobial agents, Clin. Microbiol. Rev. 19, 491-511.
9. Hamill, P., Brown, K., Jenssen, H., and Hancock, R. E. (2008) Novel anti-infectives: is host defence the answer?, Curr. Opin. Biotechnol. E-pub ahead of print. DOI: 10.1016/j.copbio.2008.10.006.
10. Hancock, R. E., and Rozek, A. (2002) Role of membranes in the activities of antimicrobial cationic peptides, FEMS Microbiol. Lett 206, 143-149.
11. Peschel, A., and Sahl, H. G. (2006) The co-evolution of host cationic antimicrobial peptides and microbial resistance, Nat. Rev. Microbiol. 4, 529-536.
12. Hilpert, K., Elliott, M. R., Volkmer-Engert, R., Henklein, P., Donini, O., Zhou, Q., Winkler, D. F., and Hancock, R. E. (2006) Sequence requirements and an optimization strategy for short antimicrobial peptides, Chem. Biol. 13, 1101-1107.
13. Hilpert, K., Volkmer-Engert, R., Walter, T., and Hancock, R. E. (2005) High-throughput generation of small antibacterial peptides with improved activity, Nat. Biotechnol. 23, 1008-1012.
14. Loose, C., Jensen, K., Rigoutsos, I., and Stephanopoulos, G. (2006) A linguistic model for the rational design of antimicrobial peptides, Nature 443, 867-869.
15. Engel, T. (2006) Basic overview of chemoinformatics, J. Chem. Inf. Model 46, 2267-2277.
16. Jenssen, H., Lejon, T., Hilpert, K., Fjell, C. D., Cherkasov, A., and Hancock, R. E. (2007) Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa, Chem. Biol. Drug Des. 70, 134-142.
17. Jenssen, H., Fjell, C. D., Cherkasov, A., and Hancock, R. E. (2008) QSAR modeling and computer-aided design of antimicrobial peptides, J. Pept. Sci. 14, 110-114.
18. Romeo, D., Skerlavaj, B., Bolognesi, M., and Gennaro, R. (1988) Structure and bactericidal activity of an antibiotic dodecapeptide purified from bovine neutrophils, J. Biol. Chem. 263, 9573-9575.
19. Wu, M., and Hancock, R. E. (1999) Improved derivatives of bactenecin, a cyclic dodecameric antimicrobial cationic peptide, Antimicrob. Agents Chemother. 43, 1274-1276.
20. Hilpert, K., and Hancock, R. E. (2007) Use of luminescent bacteria for rapid screening and characterization of short cationic antimicrobial peptides synthesized on cellulose using peptide array technology, Nat. Protoc. 2, 1652-1660.
21. Hilpert, K., Winkler, D. F., and Hancock, R. E. (2007) Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion, Nat. Protoc. 2, 1333-1349.
22. McPhee, J. B., Scott, M. G., and Hancock, R. E. (2005) Design of host defence peptides for antimicrobial and immunity enhancing activities, Comb. Chem. High Throughput Screening 8, 257-272.
23. Ostberg, N., and Kaznessis, Y. (2005) Protegrin structure-activity relationships: using homology models of synthetic sequences to determine structural characteristics important for activity, Peptides 26, 197-206.
24. Lejon, T., Strom, M. B., and Svendsen, J. S. (2001) Antibiotic activity of pentadecapeptides modelled from amino acid descriptors, J. Pept Sci. 7, 74-81.
25. Jenssen, H., Gutteberg, T. J., and Lejon, T. (2005) Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors, J. Pept Sci. 11, 97-103.
26. Frecer, V. (2006) QSAR analysis of antimicrobial and haemolytic effects of cyclic cationic antimicrobial peptides derived from protegrin-1, Bioorg. Med. Chem. 14, 6065-6074.
27. Cherkasov, A. (2003) Inductive electronegativity scale. Iterative calculation of inductive partial charges, J. Chem. Inf. Comput Sci. 43, 2039-2047.
28. Cherkasov, A. (2005) Inductive QSAR descriptors, distinguishing compounds with antibacterial activity by artificial neural network, Int. J. Mol. Sci. 6, 63-86.
29. Karakoc, E., Sahinalp, S. C., and Cherkasov, A. (2006) Comparative QSAR and fragments distribution analysis of drugs, druglikes, metabolic substances, and antimicrobial compounds, J. Chem. Inf. Model. 46, 2167-2182.
30. Cherkasov, A. (2006) Can "bacterial-metabolite-likeness" model improve odds of "in silico" antibiotic discovery? J. Chem. Inf. Model. 46, 1214-1222.
31. Yeaman, M. R., and Yount, N. Y. (2003) Mechanisms of antimicrobial peptide action and resistance, Pharmacol. Rev. 55, 27-55.
32. Suzuki, N., Suzuki, S., Duncan, G. S., Millar, D. G., Wada, T., Mirtsos, C., Takada, H., Wakeham, A., Itie, A., Li, S., Penninger, J. M., Wesche, H., Ohashi, P. S., Mak, T. W., and Yeh, W. C. (2002) Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4, Nature 416, 750-756.
33. Mullaly, S. C., and Kubes, P. (2006) The role of TLR2 in vivo following challenge with Staphylococcus aureus and prototypic ligands, J. Immunol. 177, 8154-8163.
34. Scott, M. G., Dullaghan, E., Mookherjee, N., Glavas, N., Waldbrook, M., Thompson, A., Wang, A., Lee, K., Doha, S., Hamill, P., Yu, J. J., Li, Y., Donini, O., Guarna, M. M., Finlay, B. B., North, J. R., and Hancock, R. E. (2007) An anti-infective peptide that selectively modulates the innate immune response, Nat. Biotechnol. 25, 465-472.
35. Tsuji, M., Takema, M., Miwa, H., Shimada, J., and Kuwahara, S. (2003) In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models, Antimicrob. Agents Chemother. 47, 2507-2512.
36. Falla, T. J., Karunaratne, D. N., and Hancock, R. E. (1996) Mode of action of the antimicrobial peptide indolicidin, J. Biol. Chem. 271, 19298-19303.
37. Fjell, C.D., Jenssen, H., Hilpert, K., Cheung, W.A., Panté, N., Hancock, R.E.W., and Cherkasov, A. (2009) Identification of novel antibacterial peptides by chemoinformatics and machine learning. Manuscript in preparation.
38. Bellido, F., Pechere, J. C., and Hancock, R. E. (1991) Reevaluation of the factors involved in the efficacy of new β-lactams against Enterobacter cloacae, Antimicrob. Agents Chemother. 35, 73-78.
39. Salunkhe, P., Smart, C. H., Morgan, J. A., Panagea, S., Walshaw, M. J., Hart, C. A., Geffers, R., Tummler, B., and Winstanley, C. (2005) A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance, J. Bacteriol. 187, 4908-4920.